NBIX
Neurocrine Biosciences, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$173.00+1.24%
Price as of Jul 20, 2026
NBIX financials
Neurocrine Biosciences, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B |
| Cost of revenue | $52.1M | $34.0M | $39.7M | $23.2M |
| Gross profit | $2.8B | $2.3B | $1.8B | $1.5B |
| Operating expenses | $2.2B | $1.8B | $1.6B | $1.2B |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M |
| EBITDA | $666.6M | $639.7M | $416.1M | $236.6M |
| Basic EPS | $4.81 | $3.40 | $2.56 | $1.61 |
| Diluted EPS | $4.67 | $3.29 | $2.47 | $1.56 |
| Balance sheet | ||||
| Cash & equivalents | $713.0M | $233.0M | $251.1M | $262.9M |
| Total assets | $4.6B | $3.7B | $3.3B | $2.4B |
| Total liabilities | $1.4B | $1.1B | $1.0B | $660.9M |
| Stockholders’ equity | $3.3B | $2.6B | $2.2B | $1.7B |
| Total debt | $415.3M | $455.1M | $428.4M | $262.9M |
| Net debt | -$297.7M | $222.1M | $177.3M | $0.00 |
| Cash flow | ||||
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M |
| Capital expenditure | -$34.0M | -$38.2M | -$28.3M | -$16.5M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$167.7M | -$300.0M | $0.00 | $0.00 |